- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Business transacted at the extraordinary general meeting of Aquaporin A/S | 227 | PR Newswire | Company announcementNo. 20/2025Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany reg. no.: DK28315694KONGENS LYNGBY, Denmark, Dec. 1, 2025 /PRNewswire/ -- Aquaporin A/S... ► Artikel lesen | |
| Mo | Aquaporin A/S: Business transacted at the extraordinary general meeting of Aquaporin A/S | 72 | GlobeNewswire (Europe) | Company announcement
No. 20/2025
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company reg. no.: DK28315694
Kongens Lyngby, Denmark, December 1, 2025 - Aquaporin A/S ("Aquaporin"... ► Artikel lesen | |
| 13.11. | Aquaporin A/S: Aquaporin Q3 2025 Trading Statement | 173 | PR Newswire | Company announcement
No. 19/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11. | Aquaporin A/S: Notice to convene an extraordinary general meeting | 366 | PR Newswire | Company announcement
No. 18/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| AQUAPORIN Aktie jetzt für 0€ handeln | |||||
| 07.11. | Aquaporin A/S: Update on strategic review and intention to strengthen financial position | 314 | PR Newswire | Company announcement
No. 17/2025Inside information
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS... ► Artikel lesen | |
| 21.08. | Aquaporin A/S: Aquaporin announces results for first half 2025 | 338 | PR Newswire | Company announcement No. 16/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngby aquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug. 21, 2025 /PRNewswire/... ► Artikel lesen | |
| 13.08. | AQUAPORIN A/S: Aquaporin to host half-year 2025 results webcast on August 21 | 3 | Cision News | ||
| 12.08. | Aquaporin Cuts FY Revenue Guidance, Initiates Strategic Review | 1 | RTTNews | ||
| 11.08. | Aquaporin A/S: Aquaporin lowers revenue guidance for 2025, but maintains EBITDA guidance, and initiates strategic review | 1.093 | PR Newswire | Company announcementNo. 15/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug.... ► Artikel lesen | |
| 05.08. | Aquaporin A/S: Aquaporin successfully achieves up to 20% energy savings at Kranji NEWater Factory | 329 | PR Newswire | KONGENS LYNGBY, Denmark, Aug. 5, 2025 /PRNewswire/ -- Aquaporin has successfully completed the Living Lab Project to develop the world's first biomimetic low-energy Aquaporin Inside® CLEAR... ► Artikel lesen | |
| 08.07. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons discharging managerial responsibilities | 2 | Cision News | ||
| 07.07. | AQUAPORIN A/S: Aquaporin issues warrants under a new warrant program | 2 | Cision News | ||
| 20.06. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons closely associated with persons discharging managerial responsibilities in Aquaporin | 2 | Cision News | ||
| 20.06. | AQUAPORIN A/S: Major shareholder announcement | 2 | Cision News | ||
| 12.06. | Aquaporin A/S: Aquaporin appoints Chief Executive Officer | 444 | PR Newswire | Company announcementNo. 09/2025
Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark... ► Artikel lesen | |
| 21.05. | Aquaporin A/S: Aquaporin Q1 2025 Trading Statement - maintains full-year financial guidance for 2025 | 351 | PR Newswire | Company announcementNo. 08/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark , May 21, 2025 /PRNewswire/... ► Artikel lesen | |
| 11.04. | Aquaporin A/S - Admittance to trading and official listing of new shares due to exercise of warrants | 203 | GlobeNewswire | The share capital of Aquaporin A/S has been increased. The admittance of trading and official listing of new shares will take effect as per 14 April 2025 in the ISIN below.
ISIN:
DK0061555109
Name:
Aquaporin
Volume... ► Artikel lesen | |
| 20.03. | Aquaporin A/S: Aquaporin announces full-year 2024 results | 618 | PR Newswire | Company announcementNo. 03/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, March 20, 2025 /PRNewswire/... ► Artikel lesen | |
| 20.03. | Aquaporin A/S: Aquaporin announces guidance for 2025 | 179 | GlobeNewswire (Europe) | Company announcement
No. 02/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, March 20, 2025 -... ► Artikel lesen | |
| 26.02. | Aquaporin A/S: Aquaporin improves EBIT and specifies revenue guidance for 2024 | 164 | GlobeNewswire (Europe) | Company announcement
No. 01/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, February 26, 2025... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,54 | +0,27 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| POLYRIZON | 7,330 | 0,00 % | Polyrizon Ltd.: Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform | Ra'anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,250 | +12,67 % | Why Vera Therapeutics Stock Rocked the Market on Tuesday | ||
| COGENT BIOSCIENCES | 38,980 | 0,00 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| JANUX THERAPEUTICS | 15,820 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| IMMUNOVANT | 22,020 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,150 | -3,90 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 40,405 | -1,42 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NUVALENT | 104,96 | -1,37 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,430 | -3,10 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| KYMERA THERAPEUTICS | 64,27 | -3,87 % | Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? | ||
| APOGEE THERAPEUTICS | 69,13 | +0,41 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,010 | +1,44 % | Harmony Biosciences to present Dravet syndrome trial data at AES meeting | ||
| DISC MEDICINE | 89,72 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 178,96 | -3,03 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
AQUAPORIN A/S gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,013 (+3,18 %) liegt der Kurs bei 0,422 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AQUAPORIN A/S finden Sie auf Wallstreet Online.